
    
      Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
      in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone
      Propionate/Salmeterol 500/50mcg combination (FSC 500/50) and its individual components,
      Fluticasone Propionate 500mcg (FP500) and Salmeterol 50mcg (SAL 50)
    
  